US4147787A
Expired / Lapsed
US
⏱️ 0.0 years remaining
4,5,6,7-Tetrahydro-thieno[2,3-c]-and [3,2-c]-pyridines, and therapeutic compositions containing the same
Assignee: Parcor SARL
•
Filing: 1977-12-27
•
Granted: 1979-04-03
•
Expires: 1997-12-27
Abstract
Abstract This invention relates to 4,5,6,7-tetrahydro-thieno[2,3-c]- and [3,2-c]-pyridines having the formulae: ##STR1## in which R 1 is selected from hydrogen and halogen; R 2 is selected from hydrogen and hydroxy; R 3 and R 4 , which may be the same or different, are each selected from hydrogen, C 1-6 alkyl, phenylalkyl having 1-6 carbon atoms in the alkyl moiety, and phenyl-C 1-6 alkyl substituted on the phenyl nucleus with at least a substituent selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, nitro, cyano and trifluoromethyl; and their acid addition salts. Said derivatives possess therapeutically useful anti-sludge, anti-thrombosis and blood-platelet aggregation inhibiting properties.
Inventors
- 👤 Jean-Pierre Maffrand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 21:53
CPC Classifications
C; C07; C07D; C07D495/00; C07D495/02; C07D495/04; A; A61; A61P; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
92 words
Compound selected from the compounds having the formulae: ##STR9## in which R 1 is selected from hydrogen and halogen; R 2 is selected from hydrogen and hydroxy; R 3 and R 4 , which may be the same or different, are each selected from hydrogen, C 1-6 alkyl, phenylalkyl having 1-6 carbon atoms in the alkyl moiety, and phenyl-C 1-6 alkyl substituted on the phenyl nucleus with at least one substituent selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, nitro, cyano and trifluoromethyl; and their therapeutically acceptable acid addition salts.
Claim 2
Dependent Claim
92 words
Compound selected from the compounds having the formulae: ##STR9## in which R 1 is selected from hydrogen and halogen; R 2 is selected from hydrogen and hydroxy; R 3 and R 4 , which may be the same or different, are each selected from hydrogen, C 1-6 alkyl, phenylalkyl having 1-6 carbon atoms in the alkyl moiety, and phenyl-C 1-6 alkyl substituted on the phenyl nucleus with at least one substituent selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, nitro, cyano and trifluoromethyl; and their therapeutically acceptable acid addition salts.
Claim 3
Dependent Claim
125 words
Therapeutic composition having an anti-sludge, anti-thrombosis and blood-platelet aggregation inhibiting activity comprising, as active ingredient, an effective anti-sludge or anri-thrombosis or blood-platelet aggregation inhibiting amount of a compound selected from the compounds having the formulae: ##STR10## in which R 1 is selected from hydrogen and halogen; R 2 is selected from hydrogen and hydroxy; R 3 and R 4 , which may be the same or different, are each selected from hydrogen, C 1-6 alkyl, phenylalkyl having 1-6 carbon atoms in the alkyl moiety, and phenyl-C 1-6 alkyl substituted on the phenyl nucleus with at least one substituent selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, nitro, cyano and trifluoromethyl; and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
125 words
Therapeutic composition having an anti-sludge, anti-thrombosis and blood-platelet aggregation inhibiting activity comprising, as active ingredient, an effective anti-sludge or anri-thrombosis or blood-platelet aggregation inhibiting amount of a compound selected from the compounds having the formulae: ##STR10## in which R 1 is selected from hydrogen and halogen; R 2 is selected from hydrogen and hydroxy; R 3 and R 4 , which may be the same or different, are each selected from hydrogen, C 1-6 alkyl, phenylalkyl having 1-6 carbon atoms in the alkyl moiety, and phenyl-C 1-6 alkyl substituted on the phenyl nucleus with at least one substituent selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, hydroxy, nitro, cyano and trifluoromethyl; and their therapeutically acceptable acid addition salts, together with a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
23 words
Therapeutic composition as claimed in claim 2, in unit dosage form, each unit dose containing from 0.010 g to 0.300 g active ingredient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-04-02 | 1982-10-02 | 1983-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-04-02 | 1986-10-02 | 1987-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-04-02 | 1990-10-02 | 1991-04-03 | $7700.00 | Window Closed / Lapsed |